 |
| COMBI-d: Study design |
 |
| COMBI-d: Improved OS with Dabrafenib + Trametinib vs Dabrafenib + Placebo |
 |
| Selected side effects of anti BRAF and anti MEK agents |
ASCO 2015
Dr. Long presented the results of the COMBI-d trial with an mOS benefit of 25.1 mo vs 18.7m (HR: 0.71), favoring the combination of Dabrafenib + Trametinib vs Dabrafenib + Placebo. The combination of an anti BRAF + anti MEK is highly superior to single-agent anti BRAF. These results are reinforced by the presentation, at the same meeting, of the coBRIM trial with improved PFS with another anti BRAF + antiMEK combination in the same group of patients (see blog entry).
No comments:
Post a Comment